+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

US Alzheimer's Disease Drug Market, Dosage, Price & Clinical Trials Insight 2026

  • ID: 5238618
  • Report
  • January 2021
  • Region: United States
  • 420 Pages
  • Kuick Research

FEATURED COMPANIES

  • Allergan
  • Alvogen
  • Dr. Reddy Laboratories
  • Eisai Co Ltd
  • Hoffmann- La Roche Ltd
  • Jassen Pharmaceuticals

US Alzheimer's Disease Drug Market, Dosage, Price & Clinical Trials Insight 2026 Report Highlights:

  • US Alzheimer's Disease Drug Market Opportunity: > US$ 5 Billion
  • US Accounts For More Than 40% of Global Alzheimer's Disease Drug Market
  • US Alzheimer's Disease Drug Clinical Trials: 200 Drugs in Pipeline
  • US Alzheimer's Disease Drug Availability: 9 Branded & Several Generics
  • Clinical Insight on 200 Alzheimer's Disease Drug in Pipeline
  • Marketed Branded/Generis/ Drugs Dosage, Patent, Price Insight
  • 420 Page Comprehensive Insight on Clinical & Commercial Market Landscape

Alzheimer’s disease is a neurodegenerative disorder that leads to difficulty in walking and memorizing things. The US among all the other countries in the world is showing promising opportunities to the growing Alzheimer’s disease market as the country is witnessing large number of patients getting diagnosed with the disease. The US Alzheimer’s disease drug market is set to focus on the complete transformation of the market towards a sector where prioritizing healthcare for the patients is only the aim of the researchers. Although the market has achieved all the set goals for Alzheimer’s disease have been achieved long back but still the market is progressing towards establishing novel goals for driving the future of the market.

The US Alzheimer’s disease drug market is symbiotically and synergistically moving towards introducing innovative technologies and devices for building several different novel operating models for the disease market future. It can be witnessed for US Alzheimer’s disease therapeutics market that the initial growth trend for the market, when compared with the current growth trend, is completely different. In a very few years of time period, the market has been transformed by the protocols that were followed for the development of the drugs and therapies as well as different regulatory processes that made the entire procedure of drug approval difficult. In addition to it, the market is highly supported by other important parameters such as the introduction of a number of therapies for the patient population, increase in geriatric population in the country and technologically driven clinical research studies.

The market is now affiliated with an increase in the number of launches, which is estimated to shift the market towards approximately 50% growth in the next few years. Alzheimer’s drugs in the country also represent more than 50% of the medicines available for dementia conditions, thus making the entire market of Alzheimer’s disease the largest contributor of the dementia market. In addition to it, the market is supported by high drug research designations and breakthrough discoveries that will make the market appreciate more when compared to other dementia markets in the country.

It can be well-witnessed for the US Alzheimer’s disease drug market that the overall research and development sector of the market has accelerated at a very high rate and also in a prominent way. All the drugs and therapies that are available in the market are made to achieve and respond to the critical advanced stage of the disease. The overall progress observed in the market is reflected by the strong and robust clinical pipeline that it is holding for a long period of time.

As per "US Alzheimer's Disease Drug Market, Dosage, Price & Clinical Trials Insight 2026" report findings, it is estimated that the US Alzheimer’s disease therapeutics market will be over-shadowing the growing trends and opportunities that can be observed for other emerging markets of the world. The availability of hundreds of blockbuster drugs for the patient population and robust clinical pipeline in the US research firms and bio-pharmaceutical companies are estimated to boost the overall market growth tractions. The current Alzheimer’s disease therapeutics market is now looking forward to undergoing important and novel functional collaborations and partnerships that will ultimately lead to outsourcing of hundreds of novel drugs, diagnostic tools and therapies for US patient population as well as for global patients. The future share of the Alzheimer’s disease therapeutics market is estimated to increase at a very high rate, which will eventually strengthen the entire dominance level of US at a global level. Hundreds of novel investments for the development of the market is also holding promise to advance the entire market scenario and market trends that will support high-quality drugs for future patients.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan
  • Alvogen
  • Dr. Reddy Laboratories
  • Eisai Co Ltd
  • Hoffmann- La Roche Ltd
  • Jassen Pharmaceuticals

1. US Alzheimer's Disease Drug Market Overview

2. US - Approved Alzheimer's Disease Drugs by Class
2.1 Cholinesterase Inhibitors
2.2 NMDA Receptor Agonist

3. US - New Emerging Therapies in Alzheimer's Disease
3.1 Monoclonal Antibody
3.2 Novel NMDA Receptor Agonists
3.3 Small Molecules Drug
3.4 Oral Semaglutide

4. US - Alzheimer's Disease Generic & Biosimilar Drug Market Landscape
4.1 Current Scenario & Price Differential
4.2 Reimbursement Laws & Regulations

5. Anti-Alzheimer’s Disease Drugs Classification

6. Acetylcholinesterases Inhibitor: US Market Availability, Dosage, Patent & Price Insight
6.1 Razadyne (Brand Drug)
6.2 Razadyne ER (Branded)
6.3 Aricept (Brand Drug)
6.4 Aricept ODT (Branded)
6.5 Reminyl (Branded)
6.6 Exelon (Brand Drug)
6.7 Namzaric (Brand Drug)

7. N-methyl-D-aspartate Inhibitors: US Market Availability, Dosage, Patent & Price Insight
7.1 Namenda (Brand Drug)
7.2 Namenda XR (Branded)

8. Approved Generic Drugs for Alzheimer's: US Market Availability, Dosage & Price Insight
8.1 Galantamine (Generic Drug)
8.2 Donepzil (Generic Drug)
8.3 Rivastigmine (Generic Drug)
8.4 Memantine (Generic Drug)
8.5 Ergoloid Mesylates

9. US - Alzheimer's  Disease Drugs Clinical Trials Overview
9.1 By Biomarket
9.2 By Formulation
9.3 By Organization
9.4 By Phase
9.5 By Patient Segment

10. US - Alzheimer’s Disease Drug Clinical Pipeline By Company, Indication & Phase
10.1 Unknown
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-II/III
10.9 Phase-III
10.10 Preregistration
10.11 Registered

11. US - Marketed Alzheimer’s Disease Drugs Clinical Insight
11.1 Razadyne
11.2 Namenda
11.3 Exelon Patch
11.4 Amyvid
11.5 Namzaric
11.6 Aricept
11.7 NeuraCeq
11.8 Vizamyl
11.9 Cognex

12. US Alzheimer's Disease Drug Market Dynamics
12.1 US Alzheimer's Market Favourable Parameters
12.2 US Alzheimer's  Drug Market Challenges

13. US Alzheimer Drug Market Future Prospects

14. Competitive Landscape
14.1 Allergan
14.2 Alvogen
14.3 Dr. Reddy Laboratories
14.4 Eisai Co Ltd
14.5 Hoffmann- La Roche Ltd
14.6 Jassen Pharmaceuticals
14.7 Lupin
14.8 Mylan
14.9 Novartis AG
14.10 Sun Pharma
14.11 Teva Pharmaceuticals

List of Figures
Figure 1-1: US - Alzheimer's Disease Cases (Million) by Age, 2020
Figure 1-2: US - Alzheimer's  Disease  Expected Cases by Age(%), 2020
Figure 1-3: US - Alzheimer Drug Market Oppotunity (US$ Billion), 2020 - 2026
Figure 1-4: Alzheimer's Drugs – Clinical Pipeline, 2020
Figure 2 -1: Acetylcholinesterase Inhibitors – Mechanism of Action
Figure 2-2: Memantine – Mode of Action
Figure 3-1: Designed Monoclonal Antibodies for Alzheimer Disease Discontinued Till Phase-3 Trials
Figure 4-1: US -  Alzheimer's Disease Estimated Cost of Treatment (US$ Billion), 2020
Figure 4-2: Aricept & Donepezil - Cost per Unit (US$ )
Figure 4-3: Namenda & Memantine - Cost per Unit (US$)
Figure 4-4: Namenda & Memantine – Annual Sales (US$ Million), 2019
Figure 4-5: US - Total Cost Care of Alzheimer's Treatment (US$ Billion), 2020
Figure 4-6: US - Alzheimer's Disease In-Pocket Cost & Out-Pocket Cost (%), 2020
Figure 5-1: Drugs for the Alzheimer’s Disease
Figure 6-1: Razadyne – FDA Approval & First Generic Approval Year
Figure 6-2: Razadyne – Cost of 60 Tablets of Dosage 4 mg (US$), January’2021
Figure 6-3: Razadyne – Cost of 60 Tablets of Dosage 8 mg (US$), January’2021
Figure 6-4: Razadyne – Cost of 60 Tablets of Dosage 12 mg (US$), January’2021
Figure 6-5: Razadyne– Price of 100ml Supply & Price per unit ml of Oral Solution (US$), January’2021
Figure 6 -6: Razadyne – Recommended Initial Dose & Incremented Dose (mg/day), January’2021
Figure 6-7: Razadyne – Patent Issue & Patent Expiration by US FDA
Figure 6-8: Razadyne ER – FDA Approval & First Generic Approval Year
Figure 6-9: Razadyne ER – Cost of 30 Tablets of Various Dose Regimens (US$), January’2021
Figure 6-10: Razadyne ER – Recommended Initial Dose & Incremented Dose (mg/day), January’2021
Figure 6-11: Aricept – FDA Approval Year by Dosage Forms
Figure 6-12: Aricept – Price of 30 Tablets of 5mg Drug (US$), January’2021
Figure 6-13: Aricept – Price of 21 Tablets of 10mg Drug (US$), January’2021
Figure 6-14: Aricept – Minimum Price of 30 Tablets of 10mg Drug (US$), January’2021
Figure 6-15: Aricept – Maximum Price of 30 Tablets of 10mg Drug (US$), January’2021
Figure 6-16: Aricept – Price of 30 Tablets of 23mg Drug (US$), January’2021
Figure 6-17: Aricept – Recommended & Incremented Dose for Alzheimer’s Disease (mg/day)
Figure 6-18: Aricept – Time Interval for 1st & 2nd Dose Increment (Weeks)
Figure 6-19: Aricept ODT – Cost of 30 Tablets of Dosage 5 mg (US$), January’2021
Figure 6-20: Aricept ODT – Cost of 30 Tablets of Dosage 10 mg (US$), January’2021
Figure 6-21: Aricept ODT – Recommended Initial & Incremented Dose (mg/day)
Figure 6-22: Aricept ODT – Time Interval Required for Dose Increment (Weeks)
Figure 6-23: Reminyl – USFDA & PMDA Approval Year
Figure 6-24: Reminyl – FDA Approval Year by Dosage Forms
Figure 6-25: Reminyl – Cost of 100ml & Price per ml of Oral Solution (US$), January’2021
Figure 6-26: Reminyl – Cost of 56 Tablet & Price per Tablet of 8mg & 12 mg Dose (US$), January’2021
Figure 6-27: Reminyl – Cost of 112 Tablet & Price per Tablet of 8mg (US$), January’2021
Figure 6-28: Reminyl – Recommended Initial & Incremented Dose (mg/day)
Figure 6-29: Exelon – US FDA & Europe EMEA Approval Year
Figure 6-30: Exelon – FDA Approval Year by Dosage Forms
Figure 6-31: Exelon – Price of 30 Transdermal Films of Dose 4.6 mg/24 hr (US$), January’2021
Figure 6-32: Exelon – Price of 30 Transdermal Films of Dose 9.5 mg/24 hr (US$), January’2021
Figure 6-33: Exelon – Price of 30 Transdermal Films of Dose 13.3 mg/24 hr (US$), January’2021
Figure 6-34: Exelon – Recommended Initial & Incremented Dose (mg/24 Hours)
Figure 6-35: Namzaric – FDA Approval Year by Dose
Figure 6-36: Namzaric – Forest Laboratory’s Patent Issue & Expiration Year
Figure 6-37: Namzaric – Adamas Pharmaceutical’s Patent Issue & Expiration Year
Figure 6-38: Namzaric – Price of 30 Capsules of the Drug of Dosage 7 mg – 10 mg (US$), January’2021
Figure 6-39: Namzaric – Price of 30 Capsules of the Drug of Dosage 10 mg – 14 mg (US$), January’2021
Figure 6-40: Namzaric – Price of 30 Capsules of the Drug of Dosage 10 mg – 21 mg (US$), January’2021
Figure 6-41: Namzaric – Price of 30 Capsules of the Drug of Dosage 10 mg – 28 mg (US$), January’2021
Figure 6-42: Namzaric – Recommended Initial & Incremented Dose Based on Memantine Administration (mg/day)
Figure 7-1: Namenda – FDA Approval Year by Dosage Forms
Figure 7-2: Namenda – FDA Approval & First Generic Approval Year
Figure 7-3: Namenda - Price of 49 Oral Kits (US$), January’2021
Figure 7-4: Namenda - Price of 60 Oral Tablets of Dosage 5mg (US$), January’2021
Figure 7-5: Namenda - Price of 100 Oral Tablets of Dosage 5mg (US$), January’2021
Figure 7-6: Namenda - Price of 60 Oral Tablets of Dosage 10mg (US$), January’2021
Figure 7-7: Namenda - Price of 100 Oral Tablets of Dosage 10mg (US$), January’2021
Figure 7-8: Namenda – Recommended Initial & Incremented Dose (mg/day)
Figure 7-9: US – Namenda Sales (US$ Million), 2016 - 2018
Figure 7-10: Namenda XR – FDA Approval & First Generic Approval Year
Figure 7-11: Namenda XR – Forest Laboratory’s Patent Issue & Expiration Year
Figure 7-12: Namzaric – Adamas Pharmaceutical’s Patent Issue & Expiration Year
Figure 7-13: Namenda XR – Price of 30 Capsules Supply of Various Dose Regimen (US$), January’2021
Figure 7-14: Namenda XR – Price of 90 Capsules Supply of 14mg & 28 mg Dose Regimen (US$), January’2021
Figure 7-15: Namenda XR Kit – Price of 28 Kit Supply & Price per unit Kit (US$), January’2021
Figure 7-16: Namenda XR – Recommended Initial & Incremented Dose (mg/day)
Figure 8-1: Galantamine (Generic Drug) – Cost of 30 capsules of Dosage 8 mg (US$), January’2021
Figure 8-2: Galantamine (Generic Drug) – Cost of 30 capsules of Dosage 16 mg (US$), January’2021
Figure 8-3: Galantamine (Generic Drug) – Cost of 30 capsules of Dosage 24 mg (US$), January’2021
Figure 8-4: Galantamine (Generic Drug) – Cost of 100 ml of Dosage 4 mg/ml (US$), January’2021
Figure 8-5: Galantamine (Generic Drug) – Cost of 30 Tablets of 4mg Dosage (US$), January’2021
Figure 8-6: Galantamine (Generic Drug) – Cost of 30 Tablets of 4mg Dosage (US$), January’2021
Figure 8-7: Galantamine (Generic Drug) – Cost of 60 Tablets of 4mg Dosage (US$), January’2021
Figure 8-8: Galantamine (Generic Drug) – Cost of 60 Tablets of 4mg Dosage (US$), January’2021
Figure 8-9: Galantamine (Generic Drug) – Cost of 30 Tablets of 8 mg Dosage (US$), January’2021
Figure 8-10: Galantamine (Generic Drug) – Cost of 30 Tablets of 8 mg Dosage (US$), January’2021
Figure 8-11: Galantamine (Generic Drug) – Cost of 60 Tablets of 8 mg Dosage (US$), January’2021
Figure 8-12: Galantamine (Generic Drug) – Cost of 60 Tablets of 8 mg Dosage (US$), January’2021
Figure 8-13: Galantamine (Generic Drug) – Cost of 60 Tablets of 12 mg Dosage (US$), January’2021
Figure 8-14: Galantamine (Generic Drug) – Cost of 60 Tablets of 12 mg Dosage (US$), January’2021
Figure 8-15: Galantamine Tablet & Solution – Recommended Initial & Incremented Dose (mg/day), January’2021
Figure 8-16: Galantamine ER – Recommended Initial Dose & Incremented Dose (mg/day), January’2021
Figure 8-17: Donepzil – Price of 30 Tablets of 5 mg Drug (US$), January’2021
Figure 8-18: Donepzil – Price of 30 Tablets of 10 mg Drug (US$), January’2021
Figure 8-19: Donepzil – Price of 90 Tablets of 5 mg Drug (US$), January’2021
Figure 8-20: Donepzil – Price of 100 (10X10 each) Tablets of 5 mg Drug (US$), January’2021
Figure 8-21: Donepzil – Price of 90 Tablets of 10 mg Drug (US$), January’2021
Figure 8-22: Donepzil – Price of 100 Tablets of 10 mg Drug (US$), January’2021
Figure 8-23: Donepzil – Price of 30 Tablets of 23 mg Drug (US$), January’2021
Figure 8-24: Donepzil – Price of 90 Tablets of 23 mg Drug (US$), January’2021
Figure 8-25: Donepzil – Price of 28 (4X7 each) Tablets of 5 mg Drug Disintegrating (US$), January’2021
Figure 8-26: Donepzil – Price of 30 Tablets of 5 mg Drug Disintegrating (US$), January’2021
Figure 8-27: Donepzil – Price of 28 (4X7 each) Tablets of 10 mg Drug Disintegrating (US$), January’2021
Figure 8-28: Donepzil – Price of 30 Tablets of 10 mg Drug Disintegrating (US$), January’2021
Figure 8-29: Donepzil – Recommended & Incremented Dose for Alzheimer’s Disease (mg/day)
Figure 8-30: Donepzil – Time Interval for 1st & 2nd Dose Increment (Weeks)
Figure 8-31: Rivastigmine – Price of 60 Oral Capsules of Dosage 1.5 mg (US$), January’2021
Figure 8-32: Rivastigmine – Price of 100 (10X10) Oral Capsules of Dosage 1.5 mg (US$), January’2021
Figure 8-33: Rivastigmine – Price of 500 Oral Capsules of Dosage 1.5 mg (US$), January’2021
Figure 8-34: Rivastigmine – Price of 60 Oral Capsules of Dosage 3 mg (US$), January’2021
Figure 8-35: Rivastigmine – Price of 100 (10x10) Oral Capsules of Dosage 3 mg (US$), January’2021
Figure 8-36: Rivastigmine – Price of 500 Oral Capsules of Dosage 3 mg (US$), January’2021
Figure 8-37: Rivastigmine – Price of 60 Oral Capsules of Dosage 4.5 mg (US$), January’2021
Figure 8-38: Rivastigmine – Price of 100 Oral Capsules of Dosage 4.5 mg (US$), Janaury’2021
Figure 8-39: Rivastigmine – Price of 500 Oral Capsules of Dosage 4.5 mg (US$), January’2021
Figure 8-40: Rivastigmine – Price of 60 Oral Capsules of Dosage 6 mg (US$), January’2021
Figure 8-41: Rivastigmine – Price of 60 Oral Capsules of Dosage 6 mg (US$), January’2021
Figure 8-42: Rivastigmine – Price of 100 (10X10 each) Oral Capsules of Dosage 6 mg (US$), January’2021
Figure 8-43: Rivastigmine – Price of 500 Oral Capsules of Dosage 6 mg (US$), January’2021
Figure 8-44: Rivastigmine Oral – Recommended Initial & Incremented Dose (mg/day)
Figure 8-45: Rivastigmine  Patch– Recommended Initial & Incremented Dose (mg/24 Hours)
Figure 8-46: Memantine – Price of 30 Capsules of Dosage 7 mg (US$), January’2021
Figure 8-47: Memantine – Price of 100 Capsules of Dosage 7 mg (US$), January’2021
Figure 8-48: Memantine – Price of 30 Capsules of Dosage 14 mg (US$), January’2021
Figure 8-49: Memantine – Price of 90 Capsules of Dosage 14 mg (US$), January’2021
Figure 8-50: Memantine – Price of 100 Capsules of Dosage 14 mg (US$), January’2021
Figure 8-51: Memantine – Price of 30 Capsules of Dosage 21 mg (US$), January’2021
Figure 8-52: Memantine – Price of 100 Capsules of Dosage 21 mg (US$), January’2021
Figure 8-53: Memantine – Price of 30 Capsules of Dosage 28 mg (US$), January’2021
Figure 8-54: Memantine – Price of Oral Kit for 49 (US$), January’2021
Figure 8-55: Memantine - Price of 200 ml (40 X 5 ml) of Oral Solution of Dosage 2 mg/ml (US$), January’2021
Figure 8-56: Memantine - Price of 240 ml of Oral Solution of Dosage 2 mg/ml (US$), January’2021
Figure 8-57: Memantine - Price of 360 ml of Oral Solution of Dosage 2 mg/ml (US$), January’2021
Figure 8-58: Memantine - Price of 50 Oral Tablets of Dosage 5 mg (US$), January’2021
Figure 8-59: Memantine - Price of 30 Oral Tablets of Dosage 10 mg (US$), January’2021
Figure 8-60: Memantine Tablet – Recommended Initial & Incremented Dose (mg/day)
Figure 8-61: Memantine XR – Recommended Initial & Incremented Dose (mg/day)
Figure 8-62: Ergoloid Mesylates – Average Price of 100 Tablets & Price per unit Tablet (US$), January’2021
Figure 8-63: Ergoloid Mesylates – Average Price of 10 Tablets & Price per unit Tablet (US$), January’2021
Figure 8-64: Ergoloid Mesylates – Daily, Monthly & Annual Treatment Cost (US$), January’2021
Figure 9-1: US - Number of Alzheimer's  Drugs in Clinical Trials by Biomarker,  2021 till 2026
Figure 9-2: US - Number of Alzheimer's  Drugs in Clinical Trials by Formulation,  2021 till 2026
Figure 9-3: US - Number of Alzheimer's  Drugs in Clinical Trials by Organization,  2021 till 2026
Figure 9-4: US - Number of Alzheimer's Drugs in Clinical Trials by Phase,  2021 till 2026
Figure 9-5: US - Number of Alzheimer's Drugs in Clinical Trials by Patient Segment,  2021 till 2026
Figure 12-1: US Alzheimer's Drug Market Favourable Parameters
Figure 12-2: US - Alzheimer's  DrugMarket Challenges
Figure 13-1: US – Alzheimer Disease Affected Individuals (Million), 2020, 2025 & 2050
Figure 13-2: US – Alzheimer Disease Patients (Million) by gender, 2020

Note: Product cover images may vary from those shown

Loading
LOADING...

A selection of companies mentioned in this report includes:

  • Allergan
  • Alvogen
  • Dr. Reddy Laboratories
  • Eisai Co Ltd
  • Hoffmann- La Roche Ltd
  • Jassen Pharmaceuticals
  • Lupin
  • Mylan
  • Novartis AG
  • Sun Pharma
  • Teva Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll